ArticleBrain sciences2024

Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study.

Emmanouil V Dermitzakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.